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The combined diabetes and renal control
trial (C-DIRECT) - a feasibility randomised
controlled trial to evaluate outcomes in
multi-morbid patients with diabetes and on
dialysis using a mixed methods approach
K. Griva1,2* , M. Rajeswari3, M. Nandakumar3, E. Y. H. Khoo4,5, V. Y. W. Lee2, C. G. Chua3, Z. S. Goh1,
Y. T. D. Choong2 and S. P. Newman6
Abstract
Background: This cluster randomised controlled trial set out to investigate the feasibility and acceptability of the
“Combined Diabetes and Renal Control Trial” (C-DIRECT) intervention, a nurse-led intervention based on motivational
interviewing and self-management in patients with coexisting end stage renal diseases and diabetes mellitus (DM
ESRD). Its efficacy to improve glycaemic control, as well as psychosocial and self-care outcomes were also evaluated as
secondary outcomes.
Methods: An assessor-blinded, clustered randomised-controlled trial was conducted with 44 haemodialysis patients
with DM ESRD and ≥ 8% glycated haemoglobin (HbA1c), in dialysis centres across Singapore. Patients were
randomised according to dialysis shifts. 20 patients were assigned to intervention and 24 were in usual care.
The C-DIRECT intervention consisted of three weekly chair-side sessions delivered by diabetes specialist nurses.
Data on recruitment, randomisation, and retention, and secondary outcomes such as clinical endpoints,
emotional distress, adherence, and self-management skills measures were obtained at baseline and at 12
weeks follow-up. A qualitative evaluation using interviews was conducted at the end of the trial.
Results: Of the 44 recruited at baseline, 42 patients were evaluated at follow-up. One patient died, and one
discontinued the study due to deteriorating health. Recruitment, retention, and acceptability rates of C-DIRECT
were generally satisfactory HbA1c levels decreased in both groups, but C-DIRECT had more participants with
HbA1c < 8% at follow up compared to usual care. Significant improvements in role limitations due to physical
health were noted for C-DIRECT whereas levels remained stable in usual care. No statistically significant
differences between groups were observed for other clinical markers and other patient-reported outcomes.
There were no adverse effects.
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Conclusions: The trial demonstrated satisfactory feasibility. A brief intervention delivered on bedside as part
of routine dialysis care showed some benefits in glycaemic control and on QOL domain compared with usual
care, although no effect was observed in other secondary outcomes. Further research is needed to design
and assess interventions to promote diabetes self-management in socially vulnerable patients.
Trial registration number: Trial registered with the International Standard Randomised Controlled Trial
(ISRCTN10546597). Registered 12 September 2016 (Retrospectively registered).
Keywords: Self-management, Diabetes, Kidney disease, End stage renal disease
Background
Healthcare services worldwide are placing increasing em-
phasis on patient activation towards health. Improved
self-management has been identified as key in improving
disease outcomes and quality of life for people with
long-term conditions and relevant interventions have the
potential to yield benefits for patients and health care sys-
tems alike [1].
Managing treatment and self-care is a challenge for pa-
tients with chronic multi-morbidity. Comorbid diabetes
mellitus and end-stage renal disease (DM ESRD) is a
major and emerging condition that health care services
must manage. Diabetic nephropathy is the leading cause
of ESRD, with as many as 50% of patients on renal re-
placement therapy being diagnosed with DM ESRD [2, 3].
With the diabetes epidemic and the ageing populations,
these rates are projected to rise further. DM ESRD often
leads to manifold negative health effects [4]. More than
50% of DM ESRD patients die within 2 years of dialysis
initiation [5, 6], largely due to cardiovascular complica-
tions [7], and hospital admissions for DM ESRD patients
exceed others by 26% [6]. Quality of life (QOL) is report-
edly worse for DM ESRD patients [4, 8, 9].
Self-management and adherence are particularly problem-
atic as regimen complexity demands intensify and may
compete with each other [10, 11], making it harder for pa-
tients to integrate guidelines or decide on priorities re-
garding their care [12]. In addition to dialysis, the key to
the management of DM ESRD lies in both medication ad-
herence and diet modification. DM ESRD patients often
face difficulties in glycaemic and phosphate control, which
cannot be completely addressed with medication alone
without dietary modifications. Diet is particularly challen-
ging for DM ESRD patients as they have to abide to often
complex and incompatible dietary recommendations lead-
ing to a suboptimal self-care and management [13]. Not-
ably, DM ESRD patients are known to have “poor”
records of adherence and self-management. Motivation to
self-care may thus be undermined.
There is extensive literature on value of
disease-specific programs based on self-management
principles to support behavioural changes especially in
the context of diabetes [14], and systematic reviews and
meta-analyses have shown benefits in both glycaemic
control and self-care over usual care [15–18]. Based on
such strong evidence, the American Diabetes Associ-
ation, the American Association of Diabetes Educators,
and the Academy of Nutrition and Dietetics released a
joint statement identifying self-management support as
essential for all individuals with diabetes [19]. Evidence
on multi-morbid patients however remains scarce [20],
more so for the ESRD population [21]. Interventions to
support this high-risk segment of dialysis patients are
clearly needed – especially inexpensive and low intensity
programs that can be delivered as part of routine care
and hence have the potential to become available/access-
ible to more patients. A self-management program
(HEDSMART) developed specifically for patients on
haemodialysis (HD) has shown improved clinical and be-
havioural outcomes and reductions in depression [21,
22], but proportion of patients with diabetes recruited
was low. Leveraging on this approach and following for-
mative work with DM ESRD patients [23], we have de-
veloped a brief-clinic integrated intervention for patients
with coexisting DM and ESRD currently treated with
HD, the “Combined Diabetes and Renal Control Trial”
(C-DIRECT) to support self-management for both
conditions.
To gauge its potential benefit(s) and evaluate the pos-
sibility of any design issue(s) in the protocol, [24] we
had to conduct a trial to establish the acceptability and
feasibility of the C-DIRECT. Feasibility trials are recom-
mended before investing in a full scale, costly trial, and
even before considering for use in clinical practice. The
information from this trial will be used to guide the re-
finement of a future adequately powered trial to evaluate
the effectiveness of the program for the
self-management of coexisting diabetes and ESRD.
The objective of this trial was to assess the feasibility
and acceptability of C-DIRECT. We aimed to collect
HbA1c and patient-reported outcomes to assess the po-
tential efficacy of C-DIRECT to improve glycaemic con-
trol, psychosocial, and self-care outcomes of patients
with coexisting DM ESRD compared with usual care so
as to determine the most appropriate main outcome for
the main trial.
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Method
Trial design
This feasibility study is a parallel two-arm,
assessor-blinded, clustered randomised control trial
(RCT). The trial had a 1:1 allocation ratio across study
arms and used a mixed methods approach for evaluation
of outcomes.
Ethical approval has been granted by the National Uni-
versity of Singapore Institutional Review Board (NUS
IRB 13–295) and the trial has been registered in the
ISRTCN Registry (ISRCTN10546597).
Setting and participants
Patients with DM ESRD who were undergoing haemodi-
alysis were recruited from participating dialysis centres
of the National Kidney Foundation of Singapore (NKF).
NKF is a not-for-profit organisation that provides dialy-
sis for lower and middle-income ESRD patients in
Singapore across dialysis centres located within commu-
nities island wide. Patients admitted onto program get
allocated to neighbourhood dialysis centres nearest to
their residence.
Patients were eligible for the study if they were older
than 21 years of age (the legal cut off for the definition
of adults in Singapore), had coexisting DM and ESRD,
were on HD for a minimum of 3 months, had a HbA1c
level ≥ 8% (at baseline), and were able to communicate
in English or Mandarin.
Exclusion criteria included the following: having a ser-
ious physical or mental health conditions that would
prevent or hinder study participation (consent and as-
sessments), being hospitalised, and fluent only in Malay,
Tamil or other dialects. Criteria were assessed by senior
nurse managers and using data for medical records. List
of eligible patients and preferred language of communi-
cation for those patients were provided prior to data
collection.
Sample size
The sample sizes of 30 to 50 have been recommended
for feasibility or pilot studies [25]. Consistent with the
recommendation, we sought to recruit approximately 45
eligible participants with an estimated attrition of 10%
(about 20 patients per arm).
Randomisation
Dialysis shifts (Dialysis Shift 1: Monday/ Wednesday/ Fri-
day; Shift 2: Tuesday/ Thursday/ Saturday), instead of in-
dividual participants, were the preferred unit of
randomisation to avoid treatment contamination across
groups. Randomizing by shifts rather than dialysis centres
can also potentially control for differences across centres
(number of beds; layout of space, etc) that may introduce
unforeseen bias across study arms. Block Randomisation
was undertaken following baseline assessment, using a
random number sequence produced by a
computer-generated program (randomizer.org).
Allocation concealment was undertaken such that the
managers of the dialysis centres were not aware of the
study arm allocation. The C-DIRECT intervention is de-
livered as part of usual patient care by the DM Link
nurses. Assessors that collected and analysed the data
were independent to study care team and remained
blind to study arm allocation but use of study codes. It
was not possible to blind facilitators and patients as the
intervention required input by these parties.
Intervention
Control group (usual care)
Participants in the control group received standard/
usual care for the duration of the study.
Usual care comprises regular blood tests and medical
follow ups and care by multidisciplinary team including
renal doctors, nurses, dietitians, exercise specialists, and
medical social workers. Specialist DM link nurses sup-
port diabetes care for DM ESRD. DM link nurses are
specialised renal and diabetes educators and are assigned
to cover several dialysis centres in geographical clusters
across the country (i.e. dialysis centres in the central;
north; west and east parts of Singapore).
Intervention group (C-DIRECT with usual care)
Participants allocated to C-DIRECT received usual care
as described above plus the intervention (C-DIRECT).
The theoretical framework of the C-DIRECT was based
on Social Cognition Theory and Motivational Interview-
ing (MI), aiming to empower patients to problem solve,
set goals and stimulate valued behavioural change. The
C-DIRECT intervention was modelled on the Haemodi-
alysis Self-management Intervention Randomised Trial
(HED-SMART) renal programme [26], but its content
and delivery was tailored to the needs and context of
coexisting DM ESRD, as identified in a previous mixed
methods study [27]. These sessions were delivered at
bedside (typically the first 30–60min upon cannulation
and connection to the HD machine) by DM link nurses.
The facilitators completed a 2-day group training
course to deliver the C-DIRECT intervention followed
by 2 sessions of one-to-one coaching. The training
course consisted of 1-day on self-management principles
(e.g. problem-solving; goal-setting) and 1-day on motiv-
ational interviewing (key focus on elicit-provide-elicit
framework in reference to providing clinical feedback
and advice). A MINT (Motivational Interviewing Net-
work of Trainers) trainer observed facilitators for 2 pilot
intervention sessions and coached/provided feedback as
needed to ensure consistency of delivery and fidelity to
behavioural change principles (as noted above).
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Arrangements for additional supervision during the trial
were only on need basis or as requested by intervention
facilitators.
The purpose of the sessions with patients were (a) to
explore and expand understanding and activation
around self-management behaviours and (b) to collab-
oratively set goals to work towards more effective dis-
ease management. The intervention employs the MI
framework whereby key communication microskills, i.e.
of open-ended questions, affirmations, reflections and
summaries were used to guide the intervention sessions
through the processes of engagement, focusing (target as
chosen by patients), evocation, and planning [28]. The
Elicit-Provide-Elicit framework was used to explore un-
derstanding and tailor advice/education on topics as well
as the communication of clinical feedback on lab tests
and food records. Self-management strategies included
goal setting, action planning, self-monitoring, and feed-
back (using Elicit-Provide-Elicit framework).
At each session, facilitators presented patients with an
agenda mapping chart on possible topics of discussion
and patients were invited to choose their target (i.e. fo-
cusing) for the session: i.e. diet; foot care; fluid control;
medications; blood glucose monitoring; monitoring
(eyes); or others (to invite patients to voice other con-
cerns/topics that would like to address in relation to
management of DM ESRD).
In an integrated self-management approach, sessions
were concluded with the formulation of goal-directed
action plan related to patients’ chosen topic for each ses-
sion. All goals were set either collaboratively with the
patients or by patients themselves.
A brief outline of individual session is provided below:
Session 1:
Provide clinical feedback on recent HbA1c Lab results
using the Elicit-Provide-Elicit framework; agenda map-
ping (as above); provide information/advice on chosen
topic using the Elicit-Provide-Elicit framework; goal
setting (using importance and confidence rulers to
tailor goals and behavioural contract sheet to consoli-
date implementation of behavioural goal) and food
record (3 day) assignment.
Session 2:
Review goal setting progress and problem solve
barriers (if any); revise goal set at session 1 as needed;
review and debrief food record using the Elicit-Provide
Elicit framework to provide dietary advice and support
goal setting or any behavioural changes. If no issues
with dietary management, agenda mapping (as above);
provide information/advice on chosen topic using the
elicit Provide-Elicit framework; goal setting to add new
patient-initiated goal related to topic in session 2
(using importance and confidence rulers to tailor goals
and behaviour).
Session 3:
Review goal setting progress and problems solve
barriers (if any) for goal(s) set in session 2; revise goals
as needed. Use Elicit-Provide-Elicit framework to prob-
lem solve lapses and barriers. Use agenda mapping (as
above) to address any pending important concerns;
provide information/advice on chosen topic using the
elicit Provide-Elicit framework; goal setting (using im-
portance and confidence rulers to tailor goals and be-
haviour) – conclude with E-P-E framework to provide
additional advice and links to available resources as
patients continue to move forward with their goals.
Outcomes
As this was a feasibility trial designed to inform future
trials, several types of primary and secondary outcomes
were included. These were assessed at baseline (2 weeks
before randomisation) and at follow up (12 weeks
post-baseline) by research coordinators who were
non-interventionists and independent to the patients’
care team.
Primary outcomes
The primary outcomes were feasibility of recruitment,
retention and acceptability of intervention. Feasibility
was measured by the success of recruitment (% of con-
sent to study; % of decline) and randomisation (% of
consent to randomised; % drop out following randomisa-
tion). Recruitment and randomisation rates at ≥75%
were deemed satisfactory.
Retention was measured based on attendance of ses-
sions, ability to gather data at the time points, whether
questionnaires were completed (% completion /missing
data), and delivery of the intervention. Retention rates at
≥75% follow-up rate was deemed satisfactory.
The acceptability of the intervention was measured by
drop-out rates and qualitative interviews conducted at
the end of the trial.
Secondary outcomes
Secondary outcomes were the patient’s various clinical
endpoints, and patient reported outcomes (i.e. quality of
life, distress, adherence, and self-management skills).
Clinical endpoints Data on HbA1c, biochemical
markers (phosphate and potassium levels); protein cata-
bolic rate, albumin, haemoglobin and interdialytic weight
gains were collected from the study participants before
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the C-DIRECT, and at the end of follow up. Participants
need not undergo additional blood tests as results from
routine blood tests at dialysis centres were used for
evaluation. Absolute levels and values within clinical tar-
get ranges were recorded.
Patient reported outcomes The following standardized
and psychometrically sound patient-reported measures
were administered to measure distress (Problem Areas in
Diabetes Scale - PAID and Hospital Anxiety and Depres-
sion Scale – HADS), quality of life (Kidney Disease Quality
of Life Short Form – KDQoL), adherence and self-care
(Dialysis Diet and Fluid Non-Adherence Questionnaire –
DDFQ and Summary of Diabetes Self-Care Activities –
SDSCA), and self-management skills (Diabetes Self Efficacy
Scale – DSES and Health Education Impact Questionnaire
– HEIQ). The measures are widely used in prior research
and hence allow for comparability of findings. The selection
of these measures also adheres to the core outcome set
guidelines [29], to allow comparing the effects of different
interventions in ways that maximize power and minimize
bias. Linguistically appropriate versions of the question-
naires were used, and where not available, standard
forward-backward translation procedures were applied.
Questionnaires were self-reported but to maximize the
chance of retrieving a full data set, researchers facilitated
completion of forms for patients who so requested assist-
ance with completion, by reading out the questions and/or
assisting to fill up the responses (n = 40).
Problem Areas in Diabetes Scale (PAID).
The PAID is a 20-item scale used to assess the individ-
ual’s emotional adjustment towards life with diabetes
[30–32]. Responses were rated from 0 (“not a problem”)
to 4 (“serious problem”), and scores are then trans-
formed on a 0 to 100 scale. Higher scores would indicate
greater levels of distress. A score of 50 and higher has
been recommended as a clinical significant cut-off for
diabetes-related distress [33]. The PAID was demon-
strated to have strong correlations with general emo-
tional distress, depression, diabetes self-care behaviours,
and was shown to be a reliable predictor of glycaemic
control.
Hospital Anxiety and Depression Scale (HADS).
Generic symptoms of anxiety and depression were
measured using the HADS, which was designed for
medically ill patients and has no somatic symptom
items. [34]. The HADS consists of 2 subscales of 7 items
each. Each item uses a 4-point Likert scale from 0 to 3.
A score of more than 8 on each of the subscale would
indicate presence of anxiety or depression symptoms,
and a score of more than 16 identifies caseness for the
total scale. The HADS has been used extensively with
HD and DM ESRD patients [35–38], and is shown to
have good psychometric properties [39].
Kidney Disease Quality of Life Short Form
(KDQoL).
Health-related quality of life was measured using the
KDQoL-SF version 1.3 [40]. Both the English and Man-
darin versions have been validated in the local context
[41, 42]. The KDQoL-SF comprises a generic QOL por-
tion and 43 items measuring kidney disease specific
QOL. The generic QOL portion comprises 8 subscales:
[1] physical functioning; [2] role physical; [3] pain; [4]
general health; [5] emotional well-being; [6] role emo-
tional; [7] social function; and [8] energy. These are
combined to derive the mental component summary
(MCS), physical component summary (PCS).
The kidney disease specific portion comprises nine
subscales: [1] burden of kidney disease; [2] cognitive
function; [3] dialysis staff encouragement; [4] effects of
kidney disease; [5] patient satisfaction; [6] quality of so-
cial interaction; [7] sleep; [8] social support; and [9]
symptom problem. A kidney disease component sum-
mary (KDCS) score was also calculated. All scores range
from 0 to 100, with higher scores indicating better QoL.
Dialysis Diet and Fluid Non-Adherence Question-
naire (DDFQ).
The DDFQ measures the frequency and degree of
non-adherence to diet and fluid guidelines [43]. Patients
report the number of days they were non-adherent to
diet and food in the past 14 days, which provides a score
for frequency, and will also rate their degree (from 0 -
“none” to 4 - “very severe”) in which they deviate from
their guidelines, which will indicate a severity score.
Lower scores in these domains would suggest lower
non-adherence. The DDFQ has been found to have high
criterion and construct validity.
Summary of Diabetes Self-Care Activities (SDSCA).
The SDSCA is a well-validated measure of diabetes
self-care behaviours [44]. Its six subscales assess dif-
ferent domains of diabetes self-care behaviours, in-
cluding general diet, specific diet, exercise, blood
glucose testing, foot care and smoking. Better diabetes
self-management was indicated by a higher total and
subscale scores of the average number of days in a
week the participant performs each self-care activity.
The SDSCA has been validated on diabetic ESRD pa-
tients [23], and with other diabetic populations in
Singapore [45, 46].
Diabetes Self Efficacy Scale (DSES).
The DSES is an eight-item scale measuring patients’
confidence about performing diabetes self-management
tasks [47, 48]. The patients rate their confidence in these
tasks from a scale of 0 (“not at all confident”) to 10 (“to-
tally confident”). A higher score indicates higher
self-efficacy. The scale has been widely used in patients
with diabetes [49, 50], and in one study in patients with
comorbid diabetes and ESRD [51].
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Health Education Impact Questionnaire (HEIQ).
The HEIQ is a psychometric tool to evaluate patient
reported outcomes of education and self-management
interventions for patients with chronic conditions [52].
There are eight domains in the HEIQ: [1] positive and
active engagement in life, [2] health directed behaviour,
[3] skills and techniques acquisition, [4] constructive at-
titudes and approaches, [5] self-monitoring and insight,
[6] health service navigation, [7] social integration and
support, and [8] emotional well-being, with a total of 40
questions. Participants respond to each statement by
marking on a 4-point Likert scale (from 1 - “Strongly
Disagree” to 4 - “Strongly Agree”). Higher scores indi-
cate better outcomes. The HEIQ has been used for the
assessment of self-management programmes relating to
chronic kidney disease [26, 53] and is shown to have
high construct validity and internal validity (α ranging
from 0.70 to 0.89).
Patient’s socio-demographic factors and characteristics
Participants provided socio-demographic (age, gender,
ethnicity, educations, income, relationship and employ-
ment status, living arrangements) and disease-related in-
formation (age at diagnosis, treatment modality, and
diabetes complications status) at baseline. In addition,
medical records were reviewed to extract information on
diagnosis, duration of renal replacement therapy, medi-
cation and presence of other medical conditions. The
Charlson Comorbidity Index (CCI) was calculated to es-
timate the comorbidity burden [54]. The CCI has been
found to be highly predictive of one-year mortality of
patients suffering from multi-morbid illnesses [55].
Qualitative interviews To complement the quantitative
evaluation and further explore the acceptability of CDIR-
ECT, in line with current MRC process evaluation guide-
lines [56], qualitative interviews with intervention
participants and interventionists were conducted at the
conclusion of the trial. An interview guide was used to
maintain focus on experience with program (i.e. content,
delivery and challenges), any benefit/gains gained, point
of improvements, and discussion of factors that might
impact efficacy. Interviews were audio recorded and
transcribed verbatim. Any identifiable information was
anonymized.
Statistical methods
Statistical analyses were carried out using SPSS (Statis-
tical Package for the Social Sciences). The potential ef-
fects were assessed with intention to treat (ITT) analysis
by the baseline carried forward method [57]. Complete
case analyses were conducted as sensitivity analysis. Co-
variance analysis was conducted to assess any
between-group differences in the outcomes at follow-up,
controlling for ethnicity at baseline. We added ethnicity
as a covariate as this differed significantly between
groups (see below).
As the study was exploratory and not purposefully
powered, the derived mean differences of the subscales
are reported so as to help assess the direction, and mag-
nitude of potential effects. The proportions of values
within clinical ranges (for the biomarkers and HbA1c)
were evaluated using chi square and Wilcoxon test.
Thematic analysis [58] was used to analyse transcripts
of the qualitative interviews in an iterative process,
re-examining the earlier transcripts with the new codes
derived from each round of analysis until saturation was
reached. To enhance reliability, 20% of the transcripts
were systematically coded independently by the first au-
thor (KG). Inter-coder reliability was excellent (pooled
Kappa .92).
Results
Primary outcomes
Recruitment
We screened 128 DM ESRD patients for eligibility (see Fig. 1
for CONSORT diagram). Out of them, 46 were eligible
(36%); reasons for ineligibility were: HbA1c in good control
(N = 52), did not speak English nor Mandarin (N= 15), se-
verely ill (N= 3) or hospitalised (N = 3), transferred out to
different dialysis centre (N= 2), or newly-initiated onto HD
(less than 6months) (N = 7). Of these 46 eligible patients, 1
refused to participate, and 1 consented but did not return
the baseline questionnaire, resulting in 44 enrolled patients
(95.7% of eligible patients enrolled) that were randomised to
N = 20 in C-DIRECTand N= 24 in usual care.
None of the participants withdrew after group alloca-
tion, indicating a good level of acceptability of the
randomization process.
Demographic and treatment characteristics of the trial
participants are presented in Table 1. There were no sig-
nificant differences between the two groups of partici-
pants. Despite randomisation, intervention group
consisted of more Chinese patients than usual care (χ2
[1]=5.65, p = .032), thus all subsequent statistical com-
parisons controlled for ethnicity. In a larger study, strati-
fied randomisation is recommended.
Retention
All patients completed the three sessions of the pro-
gram. At the conclusion of the study, the follow up
questionnaire was completed by N = 42 (retention rate =
95.5%) of patients. One patient in the intervention dis-
continued the study due to health deterioration and pro-
longed hospitalisation and one patient in usual care
died. Completion of individual measures was high (com-
pletion rate = 96%).
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Interviews were completed by 17 out of 20 C-DIRECT
participants and all five intervention facilitators.
Delivery of intervention
All participants completed all 3 sessions. In all the cases
the nurse facilitators were able to deliver the interven-
tion chairside as per protocol. The sessions were typic-
ally around 30 min (Mean = 25.5; SD = 12.1).
Secondary outcomes
Clinical endpoints
Table 2 shows the clinical endpoints of the study outcome
measures. Baseline observations were carried forward for
missing data at follow up (ITT). Group (C-DIRECT, Usual
Care [UC]) × Time (baseline, follow-up) ANCOVAs con-
trolling for ethnicity were performed on all clinical
markers.
There were no significant interaction effects in any of
the clinical markers suggesting no differential course
across study arms (Table 2).
ITT analyses indicated significant main effects for time
in HbA1c (F [1, 40]=6.51, p = .02) – with mean levels
across both arms significantly reduced from baseline to
follow up.
The proportion of patients within clinical targets for
HbA1c significantly increased at follow up for
C-DIRECT from 0% at baseline to N = 8 (40%) at follow
up (p = .008) where in UC only N = 4 (17%) has HbA1c
below 8% (p = .12).
Per protocol (PP) analyses indicated similar patterns of
results.
Patient reported outcomes
Table 3 depicts patient reported outcomes at baseline
and at follow up. When the recommended cut-offs
were applied, depressive and anxiety symptoms were
in the normal range (MDepression = 4.38, SDDepression =
3.59 and MAnxiety = 3.78, SDAnxiety = 3.29), with only
18.2% and 9.1% reaching or exceeding threshold for
depression or anxiety disorder (≥8) respectively.
Scores on the diabetes self-efficacy scale indicated
high levels of confidence in managing diabetes regi-
men demands, and diabetes-related distress was low
(M = 7.54, SD = 1.75). Adherence and self-care were
variable. In terms of diabetes self-care, adherence was
greater for diet and lower for exercise.
The ANCOVAS to compare study arms (C-DIRECT,
Usual Care [UC]) over Time (baseline, follow-up) while
Fig. 1 CONSORT Diagram
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Table 1 Patients’ Baseline Socio-demographic and Clinical Characteristics (n = 44)
Measure C-DIRECT (n = 20) UC (n = 24) Total Sample (N = 44)
Age in years 61.8 ± 9.4 63.3 ± 8.0 62.6 ± 8.6
Males 12 (60%) 9 (38%) 21 (48%)
Ethnicity
Chinese 13 (65%) 7 (29%) 20 (46%)
Malay 6 (30%) 17 (71%) 23 (52%)
Indian 1 (5%) 0 1 (2%)
Education (years) 6.7 ± 4.1 6.65 ± 2.7 6.9 ± 3.4
Income
< $2000 12 (60%) 7 (29%) 19 (43%)
≥ $2000 6 (30%) 4 (17%) 10 (23%)
Don’t know/ do not wish to answer 2 (10%) 13 (54%) 15 (35%)
Relationship status
Married 13 (65%) 15 (63%) 28 (64%)
Employment Status
Employed 3 (15%) 2 (8%) 5 (12%)
Living arrangement
1–2 room HDBg flat 4 (20%) 6 (25%) 10 (23%)
3–4 room HDBg flat 14 (70%) 18 (75%) 32 (73%)
5 room HDBg/ executive/maisonette 2 (10%) 0 2 (5%)
Current housing
With family 17 (85%) 23 (96%) 40 (91%)
Alone/others 3 (15%) 1 (4%) 4 (9%)
Age of diagnosis for diabetes 42.1 ± 12.0a 44.12 ± 12.4c 43.19 ± 12.1e
Duration of diabetes (months) 19.73 ± 10.2a 18.38 ± 9.1b 19.03 ± 9.5f
Age of diagnosis of CKD 51.44 ± 13.42b 58.24 ± 10.46d 55.3 ± 12.15
Duration on dialysis in years 4.37 ± 3.64 4.14 ± 2.99 4.24 ± 3.26
Charlson’s Comorbidity Index (CCI) 7.5 ± 1.40 7.13 ± 1.23
Required assistance with survey 17 (85%) 23 (96%) 40 (91%)
Note: Means are presented in M ± SD
an = 15, bn = 16, cn = 17, dn = 21, en = 32, fn = 31
gHousing Development Board
Table 2 Secondary study outcome measures Clinical endpoints
C-DIRECT Control
Variable Baseline Follow up Mean diff Baseline Follow up Mean Diff
M (SD) M (SD) M (SD) M (SD) M (SD) M (SD)
Potassium 4.67 (0.61) 4.67 (0.88) 0 (0.56) 4.61 (0.54) 4.80 (0.67) 0.20 (0.50)
Calcium 9.30 (0.68) 9.06 (0.63) −0.24 (0.72) 9.48 (0.48) 9.52 (0.46) 0.04 (0.52)
Phosphate 4.50 (1.11) 4.700 (1.15) 0.20 (1.43) 4.44 (1.06) 4.32 (1.23) −0.12 (0.95)
Haemoglobin 11.29 (1.37) 11.25 (1.31) −0.04 (1.42) 11.56 (1.24) 11.38 (0.92) −0.19 (0.81)
HbA1c (%) 9.57 (1.37) 8.78 (1.54) −0.80 (1.24)* 9.62 (1.40) 9.50 (2.05) −0.13 (1.10)*
Albumin 39.00 (2.75) 38.75 (2.79) −0.25 (1.80) 37.75 (2.75) 37.83 (2.91) 0.08 (1.67)
Interdialytic Weight Gain 3.71 (1.24) 3.41 (1.43) −0.30 (1.01) 3.43 (1.77) 3.52 (1.48) 0.09 (1.46)
*significant main effect of time observed
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Table 3 Secondary study outcome measures Patient reported outcomes
C-DIRECT Control
Variable Baseline Follow up Mean diff Baseline Follow up Mean Diff
M (SD) M (SD) M (SD) M (SD) M (SD) M (SD)
Problem Areas in Diabetes Scale 28.00 (21.10) 26.00 (21.72) −2.00 (16.65) 19.01 (14.71) 23.85 (24.34) 4.84 (20.87)
Hospital Anxiety and Depression Scale
Anxiety 3.45 (3.98) 4.10 (3.04) 0.65 (4.12) 2.83 (3.07) 3.50 (3.35) 0.67 (2.04)
Depression 5.30 (4.12) 5.30 (4.22) 0 (3.77) ^ 3.65 (2.98) 4.22 (3.88) 0.57 (3.07) ^
Kidney Disease Related Quality of Life
Physical Functioning 32.84 (10.38) 35.00 (11.99) 2.15 (8.30) 34.63 (12.14) 37.86 (10.94) 3.22 (12.87)
Role Limitation due to Physical Health 39.90 (12.58) 48.19 (9.03) 8.29 (11.34) *# 44.89 (10.75) 45.85 (10.16) 0.96 (9.11) *#
Bodily Pain 44.70 (15.81) 46.74 (13.01) 2.04 (13.06) 48.10 (11.61) 47.25 (15.32) 0.85 (13.07)
General Health 30.73 (9.19) 33.96 (6.45) 3.14 (8.64) ^ 33.69 (7.66) 34.59 (8.98) 0.90 (10.01) ^
Emotional Wellbeing 52.59 (12.10) 51.62 (13.17) −0.98 (15.63) ^ 54.79 (12.30) 49.06 (16.02) −5.73 (15.68) ^
Role Emotional 42.66 (16.16) 44.62 (10.65) 1.96 (15.21) 50.49 (7.56) 46.29 (12.80) −4.19 (13.22)
Social Functioning 46.97 (13.30) 47.99 (12.81) 1.01 (13.86) 52.36 (8.38) 49.84 (11.79) −2.52 (8.02)
Energy 42.92 (10.74) 48.15 (11.82) 5.23 (15.52) 47.75 (10.35) 50.43 (13.78) 2.68 (14.76)
Physical Composite Summary 33.34 (9.95) 38.60 (8.41) 5.26 (6.58) * 33.00 (15.33) 36.47 (15.18) 3.46 (7.78) *
Mental Composite Summary 51.60 (11.87) 51.72 (12.39) 0.11 (13.19) 63.37 (31.17) 60.15 (32.13) −3.22 (10.79)
Symptom List 75.42 (15.98) 76.82 (17.52) 1.40 (17.71) 80.82 (16.29) 79.62 (18.20) −1.20 (17.50)
Effects of Kidney Disease 81.55 (17.90) 80.89 (18.55) −0.65 (22.66) 87.50 (12.01) 78.57 (22.24) −8.93 (22.98)
Burden of Kidney Disease 27.19 (20.10) 38.75 (26.02) 11.56 (27.45) * 40.36 (28.25) 45.57 (35.67) 5.21 (24.50) *
Cognitive Function 80.67 (23.68) 81.33 (20.24) 0.67 (16.32) ^ 82.50 (19.24) 80.97 (26.29) −1.53 (24.87) ^
Quality of Social Interaction 82.00 (19.36) 86.00 (19.09) 4.00 (19.75) 84.44 (25.23) 82.64 (18.88) −1.81 (25.73)
Sleep 67.25 (17.11) 69.13 (16.21) 1.88 (19.55) 62.29 (16.33) 53.85 (22.55) −8.44 (18.98
Social Support 80.00 (19.94) 67.50 (24.47) −12.50 (16.99) * 81.94 (30.26) 79.86 (24.56) − 2.08 (28.37) *
Dialysis Staff Encouragement 81.25 (25.81) 81.25 (20.88) 0 (18.14) ^ 90.63 (18.15) 89.58 (15.49) −1.04 (22.40) ^
Patient Satisfaction 60.00 (19.04) 65.00 (24.72) 5.00 (18.81) 56.25 (16.89) 63.20 (19.64) 6.95 (18.33)
Kidney Disease Component Summary 67.57 (11.54) 68.37 (14.98) 0.80 (9.30) ^ 72.92 (8.81) 72.73 (12.39) −0.18 (13.12) ^
Dialysis Diet and Fluid Non-Adherence Questionnaire
Diet 4.65 (7.01) 10.05 (11.95) 5.40 (11.07) 4.83 (7.38) 7.58 (10.86) 2.75 (12.18)
Fluid 7.45 (11.45) 7.55 (10.12) 0.10 (7.93) 5.17 (8.18) 8.00 (10.97) 2.83 (9.80)
Summary of Diabetes Self-Care Activities Assessment
General Diet 5.03 (2.28) 3.93 (2.84) −1.10 (2.41) 5.17 (2.19) 4.50 (2.52) −0.67 (2.46)
Specific Diet 4.23 (2.04) 4.43 (1.37) 0.20 (1.74) 4.52 (1.27) 4.33 (1.07) −0.19 (1.64)
Exercise 2.55 (2.47) 3.40 (1.92) 0.85 (1.89) 2.52 (2.21) 2.85 (2.09) 0.33 (1.79)
Blood Sugar Taking 2.64 (2.51) 2.56 (2.63) −0.08 (2.05) 2.31 (2.19) 2.98 (2.39) 0.67 (1.35)
Foot Care 2.68 (2.46) 3.26 (2.63) 0.58 (2.55) 3.10 (2.57) 3.33 (2.71) 0.23 (2.77)
Diabetes Self-Efficacy Scale Total 7.11 (1.78) 7.14 (1.67) 0.03 (1.23) 7.76 (1.71) 7.71 (1.99) −0.06 (1.14)
Health Education Impact Questionnaire
Positive and Active Engagement in Life 2.81 (0.49) 3.08 (0.55) 0.28 (0.51) 2.85 (0.55) 2.88 (0.70) 0.03 (0.55)
Health Directed Behaviour 2.80 (0.73) 2.97 (0.63) 0.16 (0.59) 2.84 (0.72) 2.90 (0.61) 0.05 (0.68)
Skills and Techniques Acquisition 3.03 (0.35) 3.14 (0.43) 0.11 (0.47) 2.99 (0.49) 3.12 (0.59) 0.14 (0.54)
Constructive Attitudes and Approaches 2.93 (0.54) 3.17 (0.40) 0.24 (0.62) ^ 3.08 (0.50) 3.26 (0.64) 0.18 (0.48) ^
Self-Monitoring and Insight 3.16 (0.30) 3.39 (0.38) 0.23 (0.39) * 3.10 (0.28) 3.36 (0.34) 0.26 (0.35) *
Health Service Navigation 3.17 (0.40) 3.28 (0.44) 0.11 (0.52) 3.23 (0.42) 3.44 (0.48) 0.22 (0.35)
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controlling for ethnicity indicated only a few significant
effects in patient reported outcomes.
In terms of QOL, there was significant time (F [1,
40]=5.17, p = .03) and interaction effect for role limi-
tations due to physical health subscale of the KDQoL
[F [1, 40]=5.44, p = .03)] – post hoc comparisons
showed that although physical role limitation scores
improved for total sample, C-DIRECT participants
significantly improved more than UC in this KDQoL
subscale post intervention.
Significant time effects were also noted for the following
KDQoL subscales/ summary scores: PCS (F [1, 40]=11.79,
p = .001), burden of kidney disease, (F [1, 40]=5.30, p
= .03), and social support (F [1, 40]=5.76, p = .02). These
indicated an increase in QOL in terms of PCS and burden
but as the interaction effects were not significant, there is
no support for C-DIRECT.
All other patient reported outcomes, namely adher-
ence, diabetes self-efficacy and self-management skills
(HEIQ) remained undifferentiated over time across study
arms with the exception of a significant time effect for
the HEIQ self-monitoring/ insight domain (F [1,
40]=15.27, p < .001). This indicated an increase in
self-monitoring and insight skills, but since the inter-
action was not significant, there is no support for
C-DIRECT.
It is of note, however, that both ITT and per protocol
analyses showed that ethnicity had a significant effect for
several outcomes indicating lower QOL, self-management
skills and higher depression for Chinese relative to
non-Chinese irrespective of study arm: general health (F [1,
40]=4.00, p = .05), mental health (F [1, 40]=7.82, p = .01),
cognitive functioning (F [1, 39]=5.95, p = .02), staff encour-
agement (F [1, 40]=9.61, p = .004), and kidney disease com-
ponent score (F [1, 40]=7.13, p = .01), constructive attitudes
(F [1, 40]=22.04, p < .001), and depression (F [1, 39]=13.50,
p = .001). The effect of ethnicity on social functioning
approached but did not reach significance in ITT analyses
(F [1, 40]=3.88, p = .06).
Per protocol (PP) analyses indicated similar patterns of
results for all outcomes with the exceptions that the ef-
fect of Chinese ethnicity for social functioning, shown as
trend in ITT, was significant (F [1, 36]=4.87, p = .030).
PP analyses confirmed that although scores in role
limitations due to physical improved across sample over
time, the improvement was significantly greater in
C-DIRECT.
Qualitative analysis
Thematic analysis has identified several key themes regard-
ing the intervention’s acceptability and impact on patients’
motivation for behaviour change and self-management [59].
Intervention participants were positive about the program
describing as useful and engaging and commenting posi-
tively on facilitators.
They are here to encourage and help us, because they
care for us and do not want us to suffer from
complications. I think it is good. (R12).
We are old, and sometimes we forget, so for them
(Facilitators) to remind us, it is a good thing. I like it.
(R11).
The useful elements were reinforcements through the
regularly planned sessions, and having specific yet mod-
est goals for weekly action. Some patients also felt moti-
vated by the ‘personal agency’ approach that gave them
choices over topics of sessions.
She asked me to choose right? Want to go for exercise or
diet or medication or the leg. So I choose foot care lah.
Because, for medication I am used to it already. I take
my medicines following the time. And then exercise, I do
exercise too at home. So I told the nurse, I want to take
care of my leg. I choose for foot care. I like that
(choosing) (R34).
Diabetes has to be managed systematically and
carefully, otherwise we are doomed. I know I have to
do this – I like making my own plans and talk about
what to do every week (R5).
At the same time, participants highlighted some
barriers that they encountered, such as language, or
how failed attempts or lack of improvement in their
health, affected their motivation to actualize what has
been taught or to persist with behaviour change.
Table 3 Secondary study outcome measures Patient reported outcomes (Continued)
C-DIRECT Control
Variable Baseline Follow up Mean diff Baseline Follow up Mean Diff
M (SD) M (SD) M (SD) M (SD) M (SD) M (SD)
Social Integration and Support 2.83 (0.41) 3.13 (0.62) 0.30 (0.71) 3.00 (0.54) 3.18 (0.61) 0.19 (0.48)
Emotional Wellbeing 2.33 (0.73) 2.38 (0.72) 0.04 (0.95) 2.22 (0.63) 2.15 (0.74) −0.08 (0.60)
*significant main effect of time observed
#significant interaction effects of time and group observed
^ significant effects of ethnicity observed
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They told me to change the amount of rice I eat, so I
did. I tried repeatedly but the situation just did not
change. I felt very frustrated and I wanted to give up.
(R8).
There were other criticisms and points of improve-
ments. Patients felt that content of advice could be bet-
ter personalised and tailored to their situation and
needs. Some further added that they either heard or
already knew the information shared in the sessions
hence at times conversations were repetitive.
Anyway I know how … So not so meaningful. Just like
watching a movie… you watch it over and over again.
So many nurses have told me before, so it is not so
useful. (R14).
In general, nurses felt the intervention worked well,
and found the training, and resources helpful. They
noted that their communication skills were improved
and interactions with patients seemed easer.
Easier now to talk – before, sometimes patients
pretend to be asleep when they see me, worry about
lab results some they worry a lot… now they know this
is for them to decide, they can tell me I can help them
make goals. (RN 2).
They did however note some difficulties. Facilitators
were aware that they needed to use C-DIRECT approach
more often (e.g. eliciting patients’ knowledge) but at
times found it difficult to move away from the didactic
manner and avoiding giving expert advice. They also
commented that some patients (with many years post
DM diagnosis) may already have learned to live with
their symptoms, and thus were less interested in consid-
ering behavioural change.
I see how better to discuss with patients not tell them
what can or cannot. We did this in training but some
don’t wanna change. Some say I know better I know
my body, have diabetes for so long I know how. No
problem lah. Then it is difficult, how to motivate them
and set goals. I have to tell them to lower blood sugar
cannot let this go. Cannot. (RN 1).
Discussion
Patients with DM and ESRD represent a high-risk group
that are called to manage two chronic conditions and
could benefit from self-management interventions.
While health behaviour interventions are highly valued
by HD patients [21], the time consuming nature of HD
and scheduling considerations hinders participation and
implementation. The C-DIRECT was developed to ad-
dress this gap. To our knowledge, this is the first study
to trial a chairside intervention specifically developed for
patients with coexisting diabetes and end-stage renal dis-
ease. We aimed for C-DIRECT to be delivered in routine
care by front care staff rather than highly specialized
psychologists or other mental health professionals to en-
hance ‘in-house’ capacity and increase patient access and
acceptability. Time requirements were purposefully kept
at minimum to cater for both staff who are often under
time duress and to allow implementation during HD
session with due consideration for patients’ convenience.
We have shown that with appropriate training and
support, C-DIRECT has the potential to be integrated
into clinic practice with good recruitment and retention
rate, attesting the feasibility and receptiveness of the
program.
Qualitative interviews indicated that both patients and
facilitators derived some benefits but there were chal-
lenges around content tailoring to patients’ needs and
delivery/fidelity to non-didactic approach, which domi-
nates health care encounters. The patients appreciated
the encouragement and effort, as well as the regular
contact and reminders by the facilitators. This perceived
care and concern from nurses makes a big difference for
the patients’ experience in health care [60]. Facilitators
also showed value in improving their skills and commu-
nication approach. They appreciated the training and
coaching and reported changes in skills and attitudes
which they considered to have enhanced their practice
beyond the scope of the study.
Analysis of clinical and patient reported outcomes in-
dicated some benefits. For the clinical outcomes at
follow-up, both groups showed improvements in HbA1c
across the two assessments. The improvement in gly-
caemic control was noteworthy for C-DIRECT – HbA1c
levels decreased by an average of 0.80% in C-DIRECT
(from 9.57 to 8.78%) post intervention which is clinically
relevant [61]. Analysis of data relative to clinical targets
indicated that a significantly greater proportion of
C-DIRECT had HbA1c levels below 8% at follow up
relative to usual care. Moreover, these clinical gains were
observed in patients who had so far not been successful
in good glycaemic control (as indicated by their baseline
values). The observed effects suggest that while UC
comprising advice on diabetes care in a more traditional
didactic approach can help to improve glycaemic control
work, augmenting of UC with techniques from
self-management and motivational interviewing may be
even more beneficial. This is largely aligned with previ-
ous evidence previous evidence in the context of dia-
betes [62, 63].
The program was also shown to have important advan-
tages for C-DIRECT patients in addition to the
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improvements in glycaemic control. The observed im-
provements in role limitations due to physical health sug-
gest functional gains for C-DIRECT. The mechanisms
whereby C-DIRECT, a multimorbid disease-specific inter-
vention, produces functional benefits need to be explored
further. Nonetheless, our preliminary data suggest that a
brief clinic integrated intervention have some benefits for
patients with coexisting diabetes and ESRD in QOL and
clinical outcomes.
Interestingly, findings suggest variation in outcomes as
function of ethnicity. Chinese patients reported worse
QOL in several generic and disease specific domains,
higher levels of depression and lower scores in con-
structive attitudes and approach relative to non-Chinese,
in line with some prior work from Singapore with renal
patients and in general population [35, 64]. While more
work is needed to explore ethnic variations, our results
underscore the need for future trials to consider ethni-
city in the design, evaluation and implementation of in-
terventions. Stratified sampling is strongly advised for
future research. There is also need for a more nuanced
understanding of patient needs in delivery of care. In
terms of practice, health care providers need to be vigi-
lant for poor adjustment among Chinese patients and
consider culture-sensitive care and interventions.
While the observed improvements with this brief
chairside intervention are certainly encouraging, they
should be interpreted with caution as the study has sev-
eral limitations. Firstly, this is an RCT with a small sam-
ple size and inclusion of multiple endpoints. This was
because we aimed to explore preliminary effects and the
feasibility of a bed/chairside, clinic-integrated interven-
tion for DM ESRD patients – something that has not
been done before. This trial is not sufficiently powered
to draw any conclusions on efficacy as it allowed to cap-
ture only outcomes with high effect sizes with sufficient
precision. The small sample also led to a slightly unbal-
anced randomisation with significantly more Chinese pa-
tients in the intervention arm. However, despite the low
statistical power, this feasibility RCT served as a first step
in demonstrating the feasibility of a subsequent, larger
scale trial and can provide relevant input for larger sized
studies.
Secondly, another potential weakness is the use of a
bilingual interviewers for administration of study ques-
tionnaire when so requested/ preferred by patients. This
has facilitated participation but may have fostered social
desirability bias. Although the research staff remained
blind to study arm allocation and was independent to
patients’ renal care team and the C-DIRECT interven-
tion facilitator, this may still have introduced some
reporting bias into this subgroup of patients. CDIRECT
was offered to those fluent in English or Mandarin – we
had to exclude patients only fluent in Malay, Tamil, or
other dialects due to logistical constraints. As however
among the four official languages in Singapore (English,
Mandarin, Malay, and Tamil), English is primarily used
(83.1% of the population is literate in English) and liter-
acy in at least two is the norm (73.2% is bilingual) [65],
we believe that the program had reasonable reach in the
target population.
Thirdly, self-selection bias cannot be ruled out as well.
While the overall sample profile was representative of
DM ESRD population, those who consented may have
been more ready to change or concerned about health
matters. This readiness is “condition sine qua non” for
behaviour change and self-management.
Finally, interventionists and participants were not
blind to treatment, which may introduce bias into the
study. Hence it is suggested that future studies consider
further blinding procedures.
Conclusions
In conclusion, the trial demonstrated that this brief,
clinic integrated intervention seemed to be feasible for
the patient group and purpose studied.
The study protocol was found to be satisfactory in the
eligibility, recruitment, and retention rates as well as the
secondary outcome measure completion. Analyses of
outcome measures indicated positive changes in QoL
(role limitation due to physical health) and promising ef-
fect on HbA1c levels, with a significant increase in num-
bers of CDIRECT patients with HbA1c levels within
clinical targets post CDIRECT.
Future studies are warranted to determine whether
this brief, clinic-integrated intervention can have sub-
stantial benefits in the large, vulnerable, and growing
population of people with coexisting Diabetes and ESRD.
Of interest would be to explore the value of program for
patients on home-based dialysis modalities such as peri-
toneal dialysis and the sustainability of (any) effects over
time using long term follow up assessments.
In terms of practice, the results of this feasibility RCT
suggest that nurses can be trained in brief psychological
techniques and deliver self-management support for
these high risk patients (DM-ESRD) during HD sessions.
Due to time demands and schedule rigidity of dialysis
routines for patients and staff alike, delivering interven-
tions in time efficient manner is essential. Given this
minimum investment of time for delivery, the CDIRECT
program may of interest to dialysis front care who are at
close and regular contact with patients.
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